Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
ConditionAdvanced Malignant Solid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSinocelltech Ltd.
About this trial
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Eligibility criteria
Qualifiers
Voluntarily sign the informed consent form (ICF);
Male or female, over 18 years old;
Survival duration more than 3 months;
ECOG score ≤ 1 point;
Disqualifiers
Has participated in another clinical study within 4 weeks prior to the first dose;
Other malignancies diagnosed within 5 years prior to the enrollment;
Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases;
Significant bleeding risk;
Trial design
Treatments tested in this trial
- SCTB39-1
Treatment groups
110 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov